MX2010003542A - Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih. - Google Patents

Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih.

Info

Publication number
MX2010003542A
MX2010003542A MX2010003542A MX2010003542A MX2010003542A MX 2010003542 A MX2010003542 A MX 2010003542A MX 2010003542 A MX2010003542 A MX 2010003542A MX 2010003542 A MX2010003542 A MX 2010003542A MX 2010003542 A MX2010003542 A MX 2010003542A
Authority
MX
Mexico
Prior art keywords
mutation
nucleoside
thymidine
dapd
azt
Prior art date
Application number
MX2010003542A
Other languages
English (en)
Inventor
Raymond F Schinazi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MX2010003542A publication Critical patent/MX2010003542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a combinaciones de inhibidores de transcriptasa inversa de nucleósido antirretrovirales, y métodos para su uso en el tratamiento de infecciones retrovirales. En una modalidad, las combinaciones incluyen agentes antirretrovirales no de nucleósido timidina, tales como tenofovir-DF, abacavir, APD y DAPD, que se seleccionan para la mutación K65R y relativamente bajas dosis de zidovudina (AZT) u otros agentes antirretrovirales de nucleósido timidina. Los agentes antirretrovirales de nucleósido timidina retardan el desarrollo de la mutación K65R, y a bajas dosis, son menos probables de producir efectos secundarios. En otra modalidad, las combinaciones incluyen DAPD y AZT. DAPD retarda el desarrollo de TAMs y AZT retarda el desarrollo de la mutación K65R. En una tercera modalidad, las combunaciones incluyen agentes antivirales de nucleósido adenina, citosina, timidina, y guanina, en combinación adicional con al menos un agente antiviral adicional que trabaja vía un diferente mecanismo que un análogo de nucleósido. Esta combinación tiene el potencial de eliminar la presencia de VIH en un paciente infectado.
MX2010003542A 2007-10-02 2008-09-29 Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih. MX2010003542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99726407P 2007-10-02 2007-10-02
PCT/US2008/078207 WO2009045975A1 (en) 2007-10-02 2008-09-29 Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase

Publications (1)

Publication Number Publication Date
MX2010003542A true MX2010003542A (es) 2010-06-02

Family

ID=40526633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003542A MX2010003542A (es) 2007-10-02 2008-09-29 Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih.

Country Status (8)

Country Link
US (1) US20110053884A1 (es)
EP (1) EP2207553A4 (es)
CN (1) CN101878032A (es)
BR (1) BRPI0816498A2 (es)
CA (1) CA2701356A1 (es)
MX (1) MX2010003542A (es)
RU (1) RU2010117269A (es)
WO (1) WO2009045975A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041512A2 (en) * 2009-10-02 2011-04-07 Emory University Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
BR112014013224B1 (pt) * 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077279A (en) * 1986-05-01 1991-12-31 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6511983B1 (en) * 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
WO2006001029A2 (en) * 2004-06-25 2006-01-05 Hetero Drugs Limited Antiretroviral compositions

Also Published As

Publication number Publication date
US20110053884A1 (en) 2011-03-03
WO2009045975A1 (en) 2009-04-09
CN101878032A (zh) 2010-11-03
EP2207553A4 (en) 2010-12-29
CA2701356A1 (en) 2009-04-09
BRPI0816498A2 (pt) 2019-02-26
EP2207553A1 (en) 2010-07-21
RU2010117269A (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
Peters et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity
Balzarini Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives
IL307486A (en) Nucleoside and nucleotide analogs as antiviral agents
BR112014013224A2 (pt) inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
ECSP16085206A (es) Derivados de nucleósido 4'-sustituidos como inihbidores de la transcriptasa reversa de vih
Pastuch-Gawołek et al. Selected nucleos (t) ide-based prescribed drugs and their multi-target activity
P Burke et al. Base-modified nucleosides as chemotherapeutic agents: past and future
MX2009012433A (es) Azido nucleosidos de purina para el tratamiento de infecciones virales.
TW200612955A (en) Topical antiviral formulations
WO2012158811A3 (en) Purine monophosphate prodrugs for treatment of viral infections
MX2015009006A (es) Oligonucleotidos inhibitorios y su uso en terapia.
PE20151318A1 (es) Analogos de 2'-cloro nucleosido para infeccion por vhc
HUP0400314A2 (hu) Gyógyszer-kombinációk rák kezelésére
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
GEP20237502B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
BRPI0910455B8 (pt) análogos de carba-nucleosídeo 1’-substituído para tratamento antiviral e composição farmacêutica que os compreende
DK1881984T3 (da) Inhibitorer af nukleosidphosphorylaser og nukleosidaser
EA200701406A1 (ru) Приемлемые для лечения вич соединения
Robak New nucleoside analogs for patients with hematological malignancies
WO2010068708A3 (en) 3'-azido purine nucleotide prodrugs for treatment of viral infections
MX2010003542A (es) Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih.
Balzarini Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors
Voller et al. Anti-cancer activities of cytokinin ribosides
De Clercq Curious discoveries in antiviral drug development: The role of serendipity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal